Grace Therapeutics, Inc. (GRCE) Stock Price & Analysis
Grace Therapeutics, Inc. (GRCE) closed at USD 1.95 on Thursday, October 15, 2026, up 3.17% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.89; the Oct 15, 2026 session ranged USD 1.89–1.97 on volume of 109,289 shares. Market capitalization is $41.02M, with a 52-week range of USD 1.79–5.18 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GRCE.md
Key facts (GRCE)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 5.88 (range 3.91–7.85).
- Total return with dividends: 1Y -39.3% vs S&P 500 +18.1%; 5Y -81.3% vs S&P 500 +85.1%.
Analysts (GRCE)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 5.88 (low 3.91, high 7.85).
Total return (dividends reinvested) (GRCE)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -39.3% | -81.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -39.4% | -28.4% |
| Volatility (annualized) | 82.5% | 73.5% |
| Max drawdown | -63.2% (Apr 2026→Oct 2026) | -83.0% (Oct 2021→Sep 2023) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 1.95 |
|---|---|
| Change | ▲ 3.17% (up) |
| Previous Close | USD 1.89 |
| Open | USD 1.91 |
| Day Range | USD 1.89 – 1.97 |
| 52-Week Range | USD 1.79 – 5.18 |
| Volume | 109,289 shares |
| Market Cap | $41.02M |
| Exchange | NCM |
Technical Analysis (GRCE)
Nexqual's technical model rates GRCE "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.83 (neutral) |
| vs SMA50 | Below (USD 2.12) |
| MACD | -0.05 (negative) |
Analyst Ratings (GRCE)
Wall Street analysts rate GRCE "Buy" based on 2 analysts, with a mean price target of USD 5.88 (range USD 3.91–7.85), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.88 |
| High Target | USD 7.85 |
| Low Target | USD 3.91 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (GRCE)
| EPS Estimate | USD -0.21 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.18 ▲ beat |
| 2026-03-31 | USD -0.08 vs est -0.21 ▲ beat |
| 2025-12-31 | USD -0.19 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.34 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (GRCE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.19% |
| Current Ratio | 11.47 |
| Total Cash | $13.76M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (GRCE)
Nexqual rates Grace Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M (TTM) |
| Efficiency | Critical — ROE -36%, ROA -10.8% |
Ownership (GRCE)
| Insider Ownership | +18.68% |
|---|---|
| Institutional Ownership | +31.58% |
| Shares Outstanding | 21.04M |
| Float | 13.45M |
| Short % of Float | +9.45% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (GRCE)
Grace Therapeutics, Inc. is led by Prashant Kohli (age 53), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Prashant Kohli (age 53) |
|---|
Major Backers & Investors (GRCE)
Notable institutional backers of Grace Therapeutics, Inc. include Cerity Partners LLC, Eversept Partners, LP, Bank of America Corporation, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cerity Partners LLC | 4.04% |
| Eversept Partners, LP | 3.67% |
| Bank of America Corporation | 2.35% |
| Citadel | 1.66% |
| Maven Securities Limited | 0.95% |
| Birchview Capital, LP | 0.57% |
| Cantor Fitzgerald, L.P. | 0.48% |
| Two Sigma Investments, LP | 0.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.91% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt